69.69 +0.09 (0.13%)
After hours: 4:37PM EST
|Bid||68.00 x 100|
|Ask||74.00 x 1000|
|Day's range||69.40 - 70.14|
|52-week range||45.47 - 70.25|
|PE ratio (TTM)||37.26|
|Earnings date||1 Feb 2018|
|Forward dividend & yield||0.64 (0.91%)|
|1y target est||70.44|
Baxter International (BAX) is expected to gain from strength in Hospital Products segment on solid sales in the U.S. Fluid Systems business as well as growing demand for injectable pharmaceuticals.
Baxter's (BAX) Arisure Closed System reduces exposure risk of healthcare professionals to needles. Also, the latest development promotes safe handling of hazardous drugs.
In 3Q17, Bioverativ’s (BIVV) drug Alprolix generated revenue of $88.5 million, which reflected a rise of ~4% on a year-over-year (or YoY) basis. In 3Q17, Alprolix contributed ~32.2% of Bioverativ’s net product sales. Alprolix reported revenue of $264.2 million in the first nine months of 2017 (which ended in September 2017) compared to its revenue of $240.5 million in the first nine months of 2016.
Mallinckrodt's (MNK) strategy to streamline its business to evolve as a top-performing specialty pharmaceutical company has led the company to enter into an agreement to sell Recothrom and Preveleak to Baxter.
Baxter International shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 79 to 83.
Illumina (ILMN) harbors hopes about recent launches like NovaSeq S4 flow cell and reagent kit for its NovaSeq 6000 System. A low margin scenario due to the NovaSeq launch is a concern.
Zimmer Biomet (ZBH) fights challenges like supply delay of certain products that curb its capacity to regain lost US-based customers and net in the new ones.
We have considered four popular ratios in order to find efficient companies that have the potential to provide impressive returns
Zacks.com highlights: Chemed, Baxter International, IDEXX Laboratories, Advanced Energy Industries and Pioneer Natural Resources
Company with a favorable efficiency level generally provides impressive returns as it is believed to be positively correlated with the stock's price performance.
BAX stock plummeted in late 2016 but has witnessed a rise in recent months, trading at a 52-week high on October 27, 2017.
Baxter International's (BAX) PD (peritoneal dialysis) solutions are among the key growth drivers of the company's renal therapies business.
On November 14, 2017, Baxter International (BAX) announced a voluntary recall of one lot of its Nexterone 150 mg/100 mL Premixed Injection.